Solid-State Characterization of Mupirocin and Metronidazole
1 Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (A.R.); (D.I.); (C.T.); (L.S.); (L.-M.Ș.); (R.B.); (A.D.); (I.L.)
2 Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania;
* Correspondence: ; Tel.: +40-724-084-531
* Author to whom correspondence should be addressed.
Received: 6 Dec 2023 / Accepted: 26 Dec 2023 / Published: 17 Jan 2024
Abstract
Mupirocin is a topical antibiotic widely used to treat various skin infections caused by Gram-positive and Gram-negative bacteria, being the first-line treatment in the case of an infection with methicillin-resistant Staphylococcus aureus (MRSA). Due to the unique mechanism of action, it does not possess any cross-resistance with other antibiotics, leading to its global use in different hospital departments. The main disadvantage of mupirocin is represented by its pharmacokinetic properties, leading to the main purpose of this study, namely, to fully characterize the physicochemical properties of the active pharmaceutical ingredient. Currently, it is used in different combinations with other active substances, for example metronidazole, to decrease the risk of developing resistance to mupirocin and to improve the therapeutic response. This leads to the second purpose of this study, i.e., to characterize the physico-chemical profile of metronidazole and to find out if there are any chemical interactions between the two compounds, and to establish if there is a possibility of using them in the same pharmaceutical formulation, thus increasing the compliance of the patient to the treatment.
Keywords: mupirocin; metronidazole; thermal analysis; kinetic analysis
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Ridichie, A.; Ledeți, A.; Ivan, D.; Tomoroga, C.; Sbârcea, L.; Șuta, L.-M.; Bertici, R.; Dragomirescu, A.; Crăineanu, F.; Ledeți, I. Solid-State Characterization of Mupirocin and Metronidazole. Timisoara_Med 2024, 2023, 3.
Ridichie A, Ledeți A, Ivan D, Tomoroga C, Sbârcea L, Șuta L-M, Bertici R, Dragomirescu A, Crăineanu F, Ledeți I. Solid-State Characterization of Mupirocin and Metronidazole. Timisoara Medical Journal. 2024; 2023(2):3.
Ridichie, Amalia; Ledeți, Adriana; Ivan, Denisa; Tomoroga, Carmen; Sbârcea, Laura; Șuta, Lenuța-Maria; Bertici, Răzvan; Dragomirescu, Anca; Crăineanu, Florentin; Ledeți, Ionuț. 2024. "Solid-State Characterization of Mupirocin and Metronidazole." Timisoara_Med 2023, no. 2: 3.
Not implemented
SHARE
